2025
SJR Q1
JCR Q1 · 8,5
SCIE
Journal detail
BioDrugs
- Country
- Switzerland · Western Europe
- Type
- journal
- ISSN
-
117388041179190X
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 2,628
- Quartile Q1
- H-Index 90
- Cites/doc 8,6
- Docs (3y) 169
- Cites (3y) 1.474
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 8,5
- 5Y JIF 7,6
- JCI 1,3
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Biotechnology Q1
- Medicine (miscellaneous) Q1
- Pharmacology Q1
- Pharmacology (medical) Q1
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Oncology | Immunology | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 2,628 | 8,5 | 7,6 | 1,3 | Q1 | 90 |
| 2024 | Q1 | Q1 | 2,29 | 6,9 | 6 | 1,16 | Q1 | 84 |
| 2023 | Q1 | Q1 | 1,796 | 5,4 | 5,3 | 1,07 | Q1 | 84 |
| 2022 | Q1 | Q1 | 1,646 | 6,8 | 6,4 | 1,05 | Q1 | 84 |
| 2021 | Q1 | Q1 | 1,539 | 7,7 | 6,9 | 1,05 | Q1 | 84 |
| 2020 | Q1 | Q1 | 1,919 | 5,8 | 5,9 | 1,09 | Q1 | 84 |
| 2019 | Q1 | Q1 | 1,304 | 5,3 | 4,1 | 1,01 | Q1 | 84 |
| 2018 | — | Q1 | — | 4,9 | 4 | 1,12 | Q1 | — |
| 2017 | Q1 | Q1 | 1,038 | 3,8 | 3,1 | 0,75 | Q2 | 84 |
| 2016 | Q1 | Q2 | 1,035 | 2,8 | 2,6 | — | — | 84 |
| 2015 | Q1 | Q2 | 0,894 | 2,9 | 2,6 | — | — | 84 |
| 2014 | Q1 | Q2 | 0,875 | 3 | 2,7 | — | — | 84 |
| 2013 | Q1 | Q3 | 0,871 | 2,1 | 2,8 | — | — | 84 |
| 2012 | Q1 | Q2 | 1,106 | 2,8 | 3,2 | — | — | 84 |
| 2011 | Q1 | Q1 | 1,486 | 3,4 | 3,1 | — | — | 84 |
| 2010 | Q1 | Q1 | 1,664 | 4,2 | 3,2 | — | — | 84 |
| 2009 | — | Q1 | — | 3,5 | 2,8 | — | — | — |
| 2008 | — | Q3 | — | 2,3 | 2,3 | — | — | — |
| 2007 | — | Q2 | — | 2,3 | 2,1 | — | — | — |
| 2006 | — | Q2 | — | 2,8 | — | — | — | — |
| 2005 | — | Q3 | — | 1,7 | — | — | — | — |
| 2004 | — | Q2 | — | 1,9 | — | — | — | — |
| 2003 | — | Q2 | — | 2,3 | — | — | — | — |
| 2002 | — | Q3 | — | 1,2 | — | — | — | — |
| 2001 | — | Q4 | — | 0,5 | — | — | — | — |
| 2000 | — | Q4 | — | 0,6 | — | — | — | — |
| 1999 | — | Q4 | — | 0,6 | — | — | — | — |
| 1998 | — | Q4 | — | 0,3 | — | — | — | — |
| 1997 | — | — | — | — | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | IMMUNOLOGY | SCIE | Q1 | Q1 | 19/183 |
| 2025 | ONCOLOGY | SCIE | Q1 | Q1 | 40/333 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 19/356 |
| 2024 | IMMUNOLOGY | SCIE | Q1 | Q1 | 25/183 |
| 2024 | ONCOLOGY | SCIE | Q1 | Q1 | 46/328 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 24/352 |
| 2023 | IMMUNOLOGY | SCIE | Q1 | Q1 | 42/181 |
| 2023 | ONCOLOGY | SCIE | Q1 | Q1 | 60/322 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 32/354 |
| 2022 | IMMUNOLOGY | SCIE | Q1 | Q1 | 40/161 |
| 2022 | ONCOLOGY | SCIE | Q1 | Q1 | 49/241 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 27/278 |
| 2021 | IMMUNOLOGY | SCIE | Q1 | Q1 | 39/162 |
| 2021 | ONCOLOGY | SCIE | Q1 | Q1 | 47/245 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 23/279 |
| 2020 | IMMUNOLOGY | SCIE | Q2 | Q1 | 47/162 |
| 2020 | ONCOLOGY | SCIE | Q2 | Q1 | 70/242 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 41/276 |
| 2019 | IMMUNOLOGY | SCIE | Q1 | Q2 | 36/159 |
| 2019 | ONCOLOGY | SCIE | Q1 | Q2 | 55/244 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 23/271 |
| 2018 | IMMUNOLOGY | SCIE | Q1 | Q1 | 36/158 |
| 2018 | ONCOLOGY | SCIE | Q1 | Q1 | 52/230 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 24/267 |
| 2017 | IMMUNOLOGY | SCIE | Q2 | Q2 | 56/155 |
| 2017 | ONCOLOGY | SCIE | Q2 | Q2 | 81/223 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 49/261 |
| 2016 | IMMUNOLOGY | SCIE | Q3 | — | 86/151 |
| 2016 | ONCOLOGY | SCIE | Q3 | — | 115/217 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 100/257 |
| 2015 | IMMUNOLOGY | SCIE | Q2 | — | 74/151 |
| 2015 | ONCOLOGY | SCIE | Q3 | — | 110/213 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 85/255 |
| 2014 | IMMUNOLOGY | SCIE | Q2 | — | 66/148 |
| 2014 | ONCOLOGY | SCIE | Q2 | — | 99/211 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 80/255 |
| 2013 | IMMUNOLOGY | SCIE | Q3 | — | 105/144 |
| 2013 | ONCOLOGY | SCIE | Q3 | — | 130/203 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 140/256 |
| 2012 | IMMUNOLOGY | SCIE | Q3 | — | 71/137 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 88/197 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 88/261 |
| 2011 | IMMUNOLOGY | SCIE | Q2 | — | 50/139 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 61/196 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 58/261 |
| 2010 | IMMUNOLOGY | SCIE | Q1 | — | 29/134 |
| 2010 | ONCOLOGY | SCIE | Q1 | — | 46/185 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 39/252 |
| 2009 | IMMUNOLOGY | SCIE | Q2 | — | 39/128 |
| 2009 | ONCOLOGY | SCIE | Q2 | — | 55/166 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 56/237 |
| 2008 | IMMUNOLOGY | SCIE | Q3 | — | 73/121 |
| 2008 | ONCOLOGY | SCIE | Q3 | — | 90/143 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 114/219 |
| 2007 | IMMUNOLOGY | SCIE | Q3 | — | 67/119 |
| 2007 | ONCOLOGY | SCIE | Q3 | — | 79/132 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 95/205 |
| 2006 | IMMUNOLOGY | SCIE | Q2 | — | 51/117 |
| 2006 | ONCOLOGY | SCIE | Q2 | — | 54/127 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 61/199 |
| 2005 | IMMUNOLOGY | SCIE | Q3 | — | 80/115 |
| 2005 | ONCOLOGY | SCIE | Q3 | — | 83/123 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 108/193 |
| 2004 | IMMUNOLOGY | SCIE | Q3 | — | 67/111 |
| 2004 | ONCOLOGY | SCIE | Q3 | — | 73/123 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 88/187 |
| 2003 | IMMUNOLOGY | SCIE | Q2 | — | 50/114 |
| 2003 | ONCOLOGY | SCIE | Q2 | — | 56/120 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 59/185 |
| 2002 | IMMUNOLOGY | SCIE | Q4 | — | 91/119 |
| 2002 | ONCOLOGY | SCIE | Q3 | — | 85/114 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 115/188 |
| 2001 | IMMUNOLOGY | SCIE | Q4 | — | 104/114 |
| 2001 | ONCOLOGY | SCIE | Q4 | — | 99/107 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 167/186 |
| 2000 | IMMUNOLOGY | SCIE | Q4 | — | 102/116 |
| 2000 | ONCOLOGY | SCIE | Q4 | — | 92/103 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 151/181 |
| 1999 | IMMUNOLOGY | SCIE | Q4 | — | 101/115 |
| 1999 | ONCOLOGY | SCIE | Q4 | — | 90/105 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 143/175 |
| 1998 | IMMUNOLOGY | SCIE | Q4 | — | 113/120 |
| 1998 | ONCOLOGY | SCIE | Q4 | — | 97/104 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 165/178 |
| 1997 | IMMUNOLOGY | SCIE | — | — | — |
| 1997 | ONCOLOGY | SCIE | — | — | — |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | — | — | — |